doi: 10.1002/cbf.3303 137 MolinaroA.NemetI.Bel LassenP.ChakarounR.NielsenT.Aron-WisnewskyJ.et al
Retatrutide is the first triple agonist (GLP-1, GIP, glucagon) to reach Phase 3 clinical trials for obesity
When done properly and safely with a trusted practitioner they can be very effective for reshaping rejuvenating areas of hollowness/mild to moderate sagging
Strengthen the immune system and promote tissue repair Obesity may affect the function of the immune system, reducing the body's resistance to pathogens
Emerging studies suggest potential benefits in cardiovascular risk reduction, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome, positioning Semaglutide as a versatile therapeutic agent in endocrine and metabolic disorders
Always consult with a healthcare provider before making any changes to medication or if any new symptoms or concerns arise